Search

Ancestim

It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]

Natural Killer Cell

Other techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy. … It is also possible to culture UCB CD34+ hematopoietic stem cells (HSCs) under stimulation of IL-2, IL-15, and stem cell factor (SCF) in a system to develop NK cells.

Mirvetuximab soravtansine

Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

Alnuctamab

Bioallethrin

A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. … Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients.

Mirikizumab

[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.

Alosetron

Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes.

Phenylpropanolamine

It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. … Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.

Pozelimab

CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [A261115] The loss of CD55 can therefore induce complement hyperactivation, causing the unwanted formation of membrane-attacking complex and resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated